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P < 0.05) among fully vaccinated children (n = 101) when compared to unvaccinated 
children (n = 141). Secondly, there was no signiﬁ cant reduction in ILI and visits to 
physician among partially vaccinated children (n = 52) versus unvaccinated children 
(OR 1.54 [0.77–3.07], P = 0.24 and OR 1.81 [0.65–5.27], P = 0.30) respectively. 
CONCLUSIONS: Based upon these ﬁ ndings, it is concluded that seasonal inﬂ uenza 
vaccine is effective in reducing the ILI and visits to physician for ARI among fully 
vaccinated Indian children. Partially vaccinated children had no statistically signiﬁ cant 
protection against ILI and visits to physician. To the best of our knowledge, this is 
the ﬁ rst report on the clinical effectiveness of seasonal inﬂ uenza vaccine in healthy 
Indian children. 
PIN9
EFFICACY AND SAFETY OF RALTEGRAVIR IN TREATMENT NAIVE HIV+ 
PATIENTS: A MIXED TREATMENT COMPARISON APPROACH
LeReun C1, Tilden D2, Harvey C3, Price B3, van Bavel J3
1Independent Biostatistician, Carrigaline county, Cork, Ireland; 2THEMA Consulting Pty Ltd, 
Pyrmont, NSW, Australia; 3MSD, Sydney, NSW, Australia
OBJECTIVES: To assess the efﬁ cacy and safety of raltegravir (integrase strand transfer 
inhibitor) compared to non-nucleoside reverse transcriptase inhibitors (nevirapine, 
efavirenz) and protease inhibitors (lopinavir, atazanavir) in treatment-naive patients 
with HIV infection. METHODS: A systematic literature search identiﬁ ed seven treat-
ment naïve trials comparing raltegravir to other treatments of interest via the common 
comparator efavirenz. This network of evidence was analyzed using a Mixed Treat-
ment Comparison (MTC). Selected outcomes were the proportion of patients with 
plasma HIV RNA less than 50 copies per mL at 48 weeks (efﬁ cacy) and discontinu-
ations (safety). A Bayesian approach was chosen and implemented in WinBugs. Fixed-
effect and random-effect models were run and the most appropriate model was 
selected based on the performance of the Monte Carlo simulations and the Deviance 
Information Criterion. Results were reported as median odds ratio, relative risk, and 
risk difference of raltegravir versus each comparator and associated 95% credible 
intervals. Bayesian inference also allows for treatment to be ranked, by calculating the 
proportion of simulations in which this treatment performs “best” in terms of relative 
efﬁ cacy/safety. RESULTS: For both efﬁ cacy and safety outcomes the ﬁ xed-effect 
models were preferred. Efﬁ cacy results showed a signiﬁ cant advantage of raltegravir 
compared to atazanavir, lopinavir, and nevirapine. Raltegravir also performed numeri-
cally better than efavirenz, and overall had a 71% probability of being the more efﬁ ca-
cious treatment on this outcome. Safety results also favored Raltegravir, but 
signiﬁ cance was only reached compared to nevirapine. CONCLUSIONS: The MTC 
suggests that raltegravir has an advantage that is at least numerical and in some cases 
statistically signiﬁ cant over its comparators in term of achieving plasma HIV less than 
50 copies per mL and avoiding discontinuation, providing additional data that sup-
ports the use of raltegravir in this indication. 
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OBJECTIVES: Estimating vaccine effectiveness is crucial for policymakers. Human 
Papillomavirus (HPV) type-speciﬁ c attribution to cervical cancers and precancers is 
one key factor in this regard for HPV vaccination and cancer screening. Among a 
number of reports on HPV type prevalence, only a few investigated attributions 
considering multitype infections and sampling methods. The objective of this study 
was to elucidate HPV type-speciﬁ c attribution in Japanese women. METHODS: A 
systematic review of published studies was conducted. Sampling methods were divided 
into two categories: one group consists of studies where HPV DNA was extracted 
from exfoliated cells, and another group consists of those using tissue specimens 
obtained by biopsy or surgical resection. To elucidate interrelationships among mul-
tiple HPV types in contributing to lesion development, attribution of each HPV was 
estimated assuming a fractional allocation of multitype infection. RESULTS: The 
overall positivity for any HPV was consistently higher in the exfoliated-cell group. On 
the other hand, attribution of HPV types 16 and 18 to cervical lesions was nominally 
higher in the tissue-specimen group. Attribution of HPV types 16 and 18 to cervical 
squamous cell carcinoma (SCC) was estimated as 47.4% (95% CI: 43.8–51.1) and 
9.4% (7.5–11.7) in the tissue-specimen group and 43.3% (38.5–48.2) and 7.6% 
(5.4–10.6) in the exfoliated-cell group, respectively. CONCLUSIONS: HPV positivity 
was higher in the exfoliated-cell group while type 16/18 attribution was nominally 
higher in the tissue-specimen group. Attribution of HPV type 16 to SCCs and adeno-
carcinomas (AC) derived from tissue specimens, after adjustment for multitype infec-
tions, was ~20% lower in Japanese women compared to data previously reported for 
US women. Type 18 attribution in Japanese women was similar to the United States 
for SCC and 10% lower for AC. 
INFECTION – Cost Studies
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OBJECTIVES: GPO-VIR® S (Stavudine, Lamivudine, Navirapine) has been used in 
people living with HIV/AIDS in Thailand since 2002. Drug resistance and adverse 
drug events (ADEs) are likely to be found. To solve this problem, GPO-VIR® Z 
(Zidovudine, Lamivudine, Navirapine) has been developed since 2005. Therefore, this 
study was conducted to evaluate the cost of ADEs found in people living with HIV/
AIDS receiving GPO-vir® S compared with GPO-vir® Z. METHODS: A retrospective 
cohort study design was used to determine the ADE costs of GPO-vir® S and GPO-vir® 
Z based on provider’s perspective. Direct medical costs (i.e., drug, laboratory, hospi-
talization, administration etc. ) were directly collected from patient proﬁ les from 
March 2005 to May 2008 at Nakornping hospital, Chiangmai province, Thailand. 
Total cost and average cost per ADE were calculated. RESULTS: A total of 136 
patients were studied. Of those, 95 cases received GPO-vir® S and 41 cases received 
GPO-vir® Z. Total ADEs found were 57 and 14 in GPO-vir® S and GPO-vir® Z groups 
respectively. Lipodystrophy (52.6%) was mostly found in GPO-vir® S group while 
anemia (28.7%) was found in GPO-vir® Z group. The total cost was 923,971 baht 
and 65,594 baht in GPO-vir® S and GPO-vir® Z respectively. An average cost per 
event in GPO-vir® S group was 16,210 baht and GPO-vir® Z group was 4686 baht. 
CONCLUSIONS: Although treatment with GPO-vir®Z seems to present lower costs 
of ADEs, selection of drug regimen still need to depend on the symptoms of individual 
patient. 
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OBJECTIVES: To quantify the ﬁ nancial burden of chronic hepatitis B (CHB) infection 
and its complications in a cost-of-illness study in Vietnam, a highly endemic country 
of hepatitis B virus (HBV) infection. METHODS: The study adopted the micro-costing 
approach. For direct medical cost estimation, data were retrieved retrospectively from 
medical histories of inpatients and outpatients with various CHB infection stages in 
2008 from a large referral hospital in Vietnam. For direct nonmedical and indirect 
cost estimation, data were obtained from outpatients from the same hospital through 
face-to-face interviews. One- and two-way analyses were performed on the cost cal-
culated. RESULTS: In 2008, the total cost of CHB infection and its complications 
was estimated to be around US$ 10 billion, with 80% contributable to direct medical 
cost. Antivirals were the major cost driver in treating CHB infections. The per-patient 
total annual direct medical cost increased with the severity of the disease with the cost 
amounted to US$ 943.64 for CHB and US$ 3916.21 for hepatocellular carcinoma. 
Based on the results, if all Vietnamese patients received treatment for CHB infections, 
the estimated cost would be twice as much as the total health budget of Vietnam, 
highlighting that a signiﬁ cant proportion of CHB infections in Vietnam are not being 
treated, and the patients are bearing the extra cost out-of-pocket, or seeking treatment 
from traditional medicines. CONCLUSIONS: This study conﬁ rms that chronic HBV 
infection poses an unbearable ﬁ nancial burden for the average patient with a GDP per 
capita of around $1024, and the lack of access to treatment is a social issue in Vietnam. 
Although universal newborns vaccination against HBV has been implemented to 
reduce the number of infected subjects, more health-care investment to improve access 
and provision of affordable medications by re-examining pharmaceutical policies to 
attain equity in proper treatment for patients with CHB infections would be needed. 
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OBJECTIVES: 1) Assess the proportion of anogenital warts to the total number of 
Sexual Transmitted Infection (STI); and 2) Quantify the direct medical costs of ano-
genital warts from patient perspective. METHODS: A prospective observational study 
was conducted in STI Clinic at Bangrak Hospital, Bangkok, Thailand from June 
2008–September 2009. The proportion of anogenital warts to the total number of STI 
was calculated from the database of Bangrak Hospital. A total of 131 patients with 
clinically diagnosed anogenital warts were recruited. After baseline assessment, the 
patients had three additional follow-up-visits at day 7, month 1, and month 3. On 
each visit, patients were examined and interviewed for health-care costs, work pro-
ductivity loss and activities impairment. At month 6, telephone assessment for the 
signs of disease recurrence was done. Patients were treated according to standard 
medical practice. RESULTS: The proportion of anogenital warts to the total number 
of STI in 2008 was 14.6%. The mean age (SD) of the study subjects was 28.2 years 
(7.4 years). Males and females were approximately equal (males 51.9%, female 
48.1%). Most of them were employed (51.1%), the rest were sex workers (25.2%), 
